Elderly medical patients treated with prophylactic dosages of enoxaparin: Influence of renal function on anti-Xa activity level

Drugs and Aging

Volumn 24, Issue 1, 2007, Pages 63-71

  Mahe, Isabelle ^a   Gouin Thibault, Isabelle ^b   Drouet, Ludovic ^a   Simoneau, Guy ^a   Di Castillo, Heidi ^a   Siguret, Virginie ^b   Bergmann, Jean François ^a   Pautas, Eric ^b  

^a HÔPITAL LARIBOISIÈRE   (France)

^b HÔPITAL CHARLES FOIX   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BLOOD CLOTTING FACTOR 10A INHIBITOR; CREATININE; ENOXAPARIN;

AGED; ARTICLE; BLEEDING; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG DOSE REGIMEN; ELDERLY CARE; FEMALE; HEMATEMESIS; HEMATOTHORAX; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MELENA; MULTICENTER STUDY; PRIORITY JOURNAL; SINGLE BLIND PROCEDURE; VENOUS THROMBOEMBOLISM;

ACUTE DISEASE; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; BODY WEIGHT; CREATININE; ENOXAPARIN; FACTOR XA; FEMALE; HUMANS; KIDNEY FAILURE; KIDNEY FUNCTION TESTS; MALE; THROMBOEMBOLISM;

EID: 33846461672     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200724010-00005     Document Type: Article

References (26)

1. Heit JA, Silverstein MD, Mohr DN, et al. The epidemiology of venous thromboembolism in the community. Thromb Haemost 2001 Jul; 86 (1): 452-63
2. Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 1999; 341: 793-8002
3. Leizorovicz A, Cohen AT, Turpie AG, et al. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004; 110: 874-9
4. Cohen AT, Davidson BL, Gallus AS, et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ 2006; 332: 325-9
5. French Drug Agency. Low molecular weight heparins and haemorrhagic risk (letter) [online]. Available from URL: http://www.agmed.sante.gouv.fr [Accessed 2006 Dec 22]
6. Lim W, Dentali F, Eikelboom JW, et al. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 2006; 144: 673-84
7. Hirsch J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (3 Suppl.): 188S-203S
8. Boneu B, de Moerloose P. How and when to monitor a patient treated with low molecular weight heparin. Semin Thromb Hemost 2001; 27: 519-22
9. Hirsch J. Laboratory monitoring of low-molecular-weight heparin therapy [letter]. J Thromb Haemost 2004; 2: 1003
10. Laposata M, Green D, Van Cott EM, et al. College of American Pathologists Conference XXXI on laboratory monitoring of low-molecular-weight-heparin, danaparoid, hirudin, and related compounds, and argatroban. Arch Pathol Lab Med 1998; 122: 799-807
11. Hulot JS, Montalescot G, Lechat P, et al. Dosing strategy in patients with renal failure receiving enoxaparin for the treatment of non-ST-segment elevation acute coronary syndrome. Clin Pharmacol Ther 2005; 77: 542-52
12. Mahé I, Drouet L, Chassany O, et al. Low molecular weight heparin for the prevention of deep venous thrombosis: a suitable monitoring in elderly patients? Pathophysiol Haemost Thromb 2002; 32: 134-6
13. Bara L, Boutitie F, Samama MM, et al. Occurrence of thrombosis and haemorrhage, relationship with anti-Xa, anti-IIa activities, and D-dimer plasma levels in patients receiving a low molecular weight heparin, enoxaparin or tinzaparin, to prevent deep vein thrombosis after hip surgery. Br J Haematol 1999; 104: 230-40
14. Prandoni P, Lensing AW, Buller HR, et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 1992; 339: 441-5
15. Gouin-Thibault I, Pautas E, Siguret V. Safety profile of different low-molecular-weight heparins used at therapeutic dose. Drug Safety 2005; 28: 333-49
16. Dose-ranging trial of enoxaparin for unstable angina: results of TIMI 11A. The Thrombolysis in Myocardial Infarction (TIMI) 11A Trial Investigators. J Am Coll Cardiol 1997; 29: 1474-82
17. Mammen EF, Arcelus J, Messmore H, et al. Clinical differentiation of low molecular weight heparins. Semin Thromb Hemost 1999; 25 Suppl. 3: 135-44
18. Desjardins L, Bara L, Boutitie F, et al. Correlation of plasma coagulation parameters with thromboprophylaxis, patient characteristics, and outcome in the Medenox study. Arch Pathol Lab Med 2004; 128: 519-26
19. Sanderink GJ, Guimart CG, Ozoux ML, et al. Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment. Thromb Res 2002; 105: 225-31
20. Chow SL, Zammit K, West K, et al. Correlation of antifactor Xa concentrations with renal function in patients on enoxaparin. J Clin Pharmacol 2003; 43: 586-90
21. Rabbat CG, Cook DJ, Crowther MA, et al. Dalteparin thromboprophylaxis for critically ill medical-surgical patients with renal insufficiency. J Crit Care 2005; 20: 357-63
22. Couturaud F, Lacut K, Leroyer C, et al. Assessment of the risk and prophylactic treatment of venous thromboembolism in elderly. Pathophysiol Haemost Thromb 2004; 33: 362-5
23. Lamb EJ, Tomson CR, Roderick PJ, Clinical Sciences Reviews Committee of the Association for Clinical Biochemistry. Estimating kidney function in adults using formulae. Ann Clin Biochem 2005; 42 (5): 321-45
24. Lamb EJ, Webb MC, Simpson DE, et al. Estimation of glomerular filtration rate in older patients with chronic renal insufficiency: is the modification of diet in renal disease formula an improvement. J Am Geriatr Soc 2003; 51: 1012-7
25. Pedone C, Corsonello A, Incalzi RA, The GIFA Investigators. Estimating renal function in older people: a comparison of three formulas. Age Ageing 2006; 35: 121-6
26. Laroche ML, Charmes JP, Marcheix A, et al. Estimation of glomerular filtration rate in the elderly: Cockcroft-Gault formula versus modification of diet in renal disease formula. Pharmacotherapy 2006; 26: 1041-6